Investment Analysts’ Downgrades for August, 8th (ABUS, AGS, APPS, APRN, ATEC, AVDL, EXTR, SO, VNDA, WGO)

Investment Analysts’ downgrades for Wednesday, August 8th:

Arbutus Biopharma (NASDAQ:ABUS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. “

Playags (NYSE:AGS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “PlayAGS, Inc. is a designer and supplier of electronic gaming machines and other products and services for the gaming industry. The company’s product line-up includes Class III EGMs for commercial and Native American casinos, video bingo machines for select international markets, table game products and interactive social casino products. PlayAGS, Inc. is headquartered in Las Vegas, Nevada. “

Digital Turbine (NASDAQ:APPS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Digital Turbine Inc. offers products and solutions for mobile operators, device OEMs and third parties. The company’s product include DT Ignite(TM), a mobile device management solution with targeted app distribution capabilities, DT IQ(TM), a customized user experience and app discovery tool, DT Marketplace(TM), an application and content store and DT Pay(TM), a content management and mobile payment solution. It operates primarily in Berlin, Singapore and Sydney. Digital Turbine, Inc., formerly known as Mandalay Digital Group, Inc., is headquartered in Austin, Texas. “

Blue Apron (NYSE:APRN) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Blue Apron Holdings, Inc. provides recipes and fresh ingredients for making home cooking accessible. It product consists of Blue Apron Meals, Blue Apron Wine, the Blue Apron Market and BN Ranch, a premium supplier of grass-fed beef and pasture-raised poultry. Blue Apron Holdings, Inc. is headquartered in New York. “

Alphatec (NASDAQ:ATEC) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company’s principal product offering includes a variety of spinal implant products and systems consisted of components, such as spine screws and rods, spinal spacers, plates, and various biologics offerings. Alphatec Holdings, Inc. is headquartered in Carlsbad, California. “

Avadel Pharmaceuticals (NASDAQ:AVDL) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates primarily in Ireland, USA and France. Avadel Pharmaceuticals plc, formerly known as Flamel Technologies SA, is headquartered in Lyon, France. “

Extreme Networks (NASDAQ:EXTR) was downgraded by analysts at Needham & Company LLC from a buy rating to a hold rating.

Southern (NYSE:SO) was downgraded by analysts at Guggenheim from a buy rating to a neutral rating.

Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “

Winnebago Industries (NYSE:WGO) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Winnebago’s fourth-quarter earnings estimates are going down of late. The debt taken by the company to acquire Grand Design in October 2016 is burdening its financial position. Further, its Motorized segment is facing challenges, which might hamper Winnebago’s financials. Also, the company’s agreement to repurchase default vehicles at a reduced price from dealers will escalate its expenses. Moreover, over the past three months, shares of Winnebago have underperformed the industry it belongs to.”

Wingstop (NASDAQ:WING) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Wingstop Inc. franchises and operates restaurants. The Company’s operating segment consists of Franchise segment and Company segment. It offers cooked-to-order, hand-sauced and tossed chicken wings. Wingstop Inc. is headquartered in Dallas, Texas. “

Willis Towers Watson (NASDAQ:WLTW) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Willis Towers’ second-quarter 2018 earnings beat the Zacks Consensus Estimate and also improved year over year, mainly on higher revenues. Shares of the company have underperformed the industry year to date. Escalating expenses, rising debt-level and adverse forex remain its key concerns.  But, it is set to deliver value via incremental revenue growth, cost synergies and tax efficiencies besides unlocking the balance sheet capacity. Focus on realizing operational efficiencies, investing in new growth avenues and strengthening its client services bode well for the company. Its inorganic growth story remains impressive and helps leverage strengths to penetrate deeper into the markets and expand international presence. Willis Towers expects adjusted earnings per share between $9.88 and $10.12, organic revenue growth of about 4% and EBITDA to be around 25% in 2018.”

Wabash National (NYSE:WNC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Wabash National Corporation is one of the leading manufacturers of semi trailers in North America. Established in 1985, the company specializes in the design and production of dry freight vans, refrigerated vans, flatbed trailers, drop deck trailers, and intermodal equipment. Its innovative core products are sold under the DuraPlate, ArcticLite, and Eagle brand names. The company operates two wholly owned subsidiaries: Transcraft Corporation, a manufacturer of flatbed and drop deck trailers; and Wabash National Trailer Centers, a retail distributor of new and used trailers and aftermarket parts throughout the U.S. and Canada. “

Weyerhaeuser (NYSE:WY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Weyerhaeuser Company reported better-than-expected results in the second quarter of 2018, with earnings and sales surpassing estimates by 7.3% and 3.5%, respectively, buoyed by strong housing market fundamentals. Earnings and revenues increased 57.1% and 14.2%, respectively, courtesy of higher demand and improving margin profile. In the quarters ahead, the company is poised to benefit from the improving housing markets in the United States. Also, the company will gain from its inorganic policies and cost-control measures. Operational initiatives are anticipated to yield $40-$50 million benefits for the Timberlands segment and $40-$60 million for the Wood Products segment. Weyerhaeuser shares have underperformed its industry year-to-date. However, earnings estimates for 2018 and 2019 are trending upward over the past 30 days. Yet, unfavorable foreign currency movements and industry competition might restrict its growth in the quarters ahead.”

Receive News & Ratings for Arbutus Biopharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply